BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Both of Genzyme's products are indicated for the treatment ... of their plant cell technology platform with this lead drug to perhaps provide a more cost-effective therapy,” he says, adding ...
Genzyme continued to drive growth for Sanofi ... analysts predicting sales of several billion dollars a year for the drug. Sanofi said the consolidation of Bioverativ, the haemophilia specialist ...
The drug, IONIS-AZ5-2.5RX ... Developed in partnership with Sanofi's Genzyme unit, patisiran is currently under review in the US and EU. If approved Alnylam will market patisiran in the US ...
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin ...
Plan now to have your poster included in the 2025 Drug Discovery & Development Virtual Event. Submission is free. Submit your abstract here. Our virtual conference allows you to participate in a ...
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. The field of ...
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...
As a result, 170 clinical questions were provided by experts from 41 EUSTAR centres. These questions were then categorised by drug (class) and aggregated with the clinical questions from 2009; ...
After hours: February 18 at 5:17:49 PM EST Loading Chart for IGMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results